3D hESC exosomes enriched with miR-6766-3p ameliorates liver fibrosis by attenuating activated stellate cells through targeting the TGFβRII-SMADS pathway.
Ning WangXiajing LiZhiyong ZhongYaqi QiuShoupei LiuHaibin WuXianglian TangChuxin ChenYingjie FuQicong ChenTingting GuoJinsong LiShuai ZhangMark A ZernKeqiang MaBailin WangYimeng OuWeili GuJie CaoHonglin ChenYuyou DuanPublished in: Journal of nanobiotechnology (2021)
Our results showed that miR-6766-3p in the 3D-hESC-Exosomes inactivates smads signaling by restraining TGFβRII expression, attenuated LX2 cell activation and suppressed liver fibrosis, suggesting that 3D-hESC-Exosome enriched-miR-6766-3p is a novel anti-fibrotic therapeutics for treating chronic liver disease. These results also proposed a significant strategy that 3D-Exo could be used as natural nanoparticles to rescue liver injury via delivering antifibrotic miR-6766-3p.
Keyphrases
- liver fibrosis
- liver injury
- transforming growth factor
- drug induced
- mesenchymal stem cells
- epithelial mesenchymal transition
- induced apoptosis
- stem cells
- poor prognosis
- cell therapy
- cell cycle arrest
- single cell
- systemic sclerosis
- small molecule
- signaling pathway
- cancer therapy
- mouse model
- endoplasmic reticulum stress
- binding protein
- cell death
- cell proliferation
- bone marrow
- long non coding rna